A Phase 2 interventional study of LY4005130 and Placebo in Vitiligo and Non-Segmental Vitiligo (NSV), sponsored by Eli Lilly and Company. Recruiting at 35 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).
Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study will last approximately 48 weeks, including screening.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
This study's planned enrollment of 66 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Browse Vitiligo studies →Eli Lilly and Company is the lead sponsor of 2,106 studies on the registry; 152 are open to participants now.
Of its 536 completed or terminated interventional studies of FDA-regulated products, 357 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible participants must have the following at both screening and baseline:
Exclusion Criteria:
LY4005130 administered intravenously (IV)
Drug: LY4005130
Placebo administered IV
Drug: Placebo
Administered IV
Administered IV
Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75
Time frame: Week 24
Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 75
Time frame: Week 24
Pharmacodynamics (PD): Change from Baseline in Gene Expression of Select Genes from Skin Biopsy
Time frame: Baseline, Week 24
Pharmacokinetics (PK): Observed Trough of LY4005130 Serum Concentration
Time frame: Week 24
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.
Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY4005130